Celleron Therapeutics

Celleron Therapeutics was a clinical-stage University of Oxford spinout focused on the clinical development of new drugs against unmet cancers, based at the Magdalen Centre on the Oxford Science Park. Its stated vision was to build a global pipeline of clinical products that are safe and effective in unmet indications, supported by a precision medicine platform that matches candidate therapies to the patients most likely to respond. The company ran Phase I clinical work on personalised medicines for cancer patients before, in late 2022, merging with fellow Oxford spinout Argonaut Therapeutics to form IngenOx Therapeutics, a combined business targeting the treatment of immunologically cold tumours.